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Introduction
Since the revolutionary method of reprogramming somatic cells by retroviral vectors in 2006, (Takahashi and Yamanaka, 2006) subsequent studies later confirmed the generation of induced pluripotent stem cells (iPSCs) from human by forced expression using a panel of pluripotency factors (KLF4, Oct-3/4, Sox2 and c-Myc) (Wernig et al., 2007; Takahashi et al., 2007; Park et al., 2008) . These iPSCs were indistinguishable from embryonic stem cells, with the ability to differentiate into various cell types. However, the use of genome-integrating retroviruses in these reprogramming methods, remain an obstacle for iPSC application in a clinical setting as it may cause unpredictable genetic dysfunction (Yamanaka 2007; . Furthermore, a case of insertional mutagenesis in patient treated with retroviral mediated gene therapy limits the potential of iPSC generated from retrovirus delivery to be used in clinical settings (Hacein-Bey-Abina et al., 2003) . To address these limitations, few strategies in silencing the transgenes in lentivirus delivery such as using inducible expression system (Brambrink et al., 2008; Soldner et al., 2009) , has been reported. Other than viral delivery, transient transfection of piggyBac transposon with Cre-mediated excisable system has also been developed albeit with lower transfection efficiency . Although all of these methods may provide a safer DNA-based reprogramming, integrative reprogramming could still induce genetic and epigenetic modification which resulted in somatic coding mutations (Gore et al., 2011) .
Since then, many strategies to avoid random integration in reprogrammed cells has been explored through non-genetic manipulation techniques using Sendai virus (SeV) (Fusaki et al., 2009) , synthetic mRNA (Warren et al., 2010) , mirRNA (Miyoshi et al., 2011) and episomal plasmid (Yu et al., 2009) . In terms of reprogramming efficiencies, mRNA is reported to be higher than episomal and SeV but a survey throughout the reprogramming laboratory community around the world reveals 41% of the respondents could not achieved successful reprogramming by RNA method (Schlaeger et al., 2015) . Thus, while highly efficient, RNA reprogramming proved to be challenging even in experienced laboratories. In terms of potential usage in clinical setting, episomal reprogramming method has been reported to be robust with higher reprogramming efficiencies than mRNA method in patient derived primary cell lines even under feeder free settings (Goh et al., 2013) . However, among the limitations of episomal reprogramming are its low efficiency and elaborate combination of reprogramming factors other than the established four (Yu et al., 2009) . Recent study also reported that further optimisation of culture condition is needed to achieve a complete transgene free reprogramming using episomal plasmids (Li et al., 2016) .
Another completely different approach towards transgene free cell reprogramming is through the usage of small molecules and chemicals. In 2008 paper, Huangfu et al., has reported the use of histone deacetylase (HDAC) inhibitor, Valproic Acid (VPA) to improve reprogramming efficiencies (Huangfu et al., 2008) . Since then, the usage of small molecules and chemicals to facilitate reprogramming through induction or by replacing one or two reprogramming factors have been widely explored (Lyssiotis et al., 2009; Shi et al., 2008) . Small molecules and chemicals could modulate epigenetic mechanism and activate endogenous gene expressions through various signaling pathways in rapid, reversible and dose dependent manner (Huangfu et al., 2008; Mikkelsen et al., 2008) . Although the usage of chemicals allows the ease of handling and administration, a comprehensive downstream screening is needed should it be used in clinical settings.
Protein-based delivery gained attention with the discovery that treatment of somatic cells with embryonic carcinoma (EC) and embryonic stem cell (ESC) cellular protein extracts could induced pluripotency and epigenetic reprogramming (Taranger et al., 2005); Freberg et al., 2007) . Both studies relied on the permeabilization of cell membranes to facilitate delivery of cell extracts into cells. Permeabilization of cell membrane is crucial as the absence of streptolysin-O (SLO) treatment hindered the up-regulation of pluripotency genes (Bru et al., 2008) . In 2010 paper, Cho et al., thoroughly explored the potential of protein-based reprogramming and reported a successful generation of human iPSC using only a single transfer of ESC-derived protein extracts (Cho et al., 2010) . Hence, protein-based delivery is thought to be a potential alternative in reprogramming cells.
By using cell permeable protein transduction approach, protein could be delivered easily into cells without the use of permeabilization agent such as SLO (Ford et al., 2001) .
Protein transduction method was also shown to be having higher advantage than viral transgene delivery in vivo (Barka and Van der Noen, 1996; Barka et al., 2000) . This delivery method ensures no genomic integration and is a practical reprogramming alternative in clinical settings. The protocol using recombinant proteins is straightforward, and there is certainly no need for integration-free colonies selection. Furthermore, protein reprogramming allows better timing and control of reprogramming factors delivery in a concentration-dependent manner.
One concern that should be addressed is the relatively low efficiency of these protein-based reprogramming. However, with recent progress in this field, a complete exogene-free iPSC cell line could possibly be generated using a highly efficient protein-based reprogramming. In this review, we discuss the various types of protein transduction system, their mechanism, and introduction to HIV-TAT derived transduction systems and its variations. In addition, the recent progress in protein-based delivery application in iPSC cell reprogramming is also reviewed.
Protein Transduction Technology
Protein transduction can be best described as the introduction of proteins into target cells from the external environment. Some proteins and peptides are capable of being taken up by cells or can penetrate the cell membrane, when introduced exogenously (Ford et al., 2001) . These proteins and peptides, usually either cytokines, homeoproteins or transcription factors, exhibit the unique properties of efficient translocation across cell membrane. This unique translocation is due to the presence of short amino acid sequences within the proteins, mediating cellular entry; which were identified as protein transduction domains (PTDs). PTDs are sometimes termed 'cell permeable proteins' (CPP) or 'membrane translocating sequences' (MTS) (Beerens et al., 2003) . This technology has opened new avenues to transfer proteins and other molecules into target cells for therapeutic purposes.
PTDs that chemically fuse to other proteins confer the ability to similarly penetrate the cell membrane and even the nucleus. The three most widely studied PTDs are the Drosophila antennapeptide (Antp), the herpes simplex virus VP22 protein, and the HIV TAT protein transduction motif (Ford et al., 2001; Beerens et al., 2003; Noguchi and Matsumoto, 2006b) .
These PTDs are different in terms of their amino acid sequence and length (Table 1 ) (Schwarze et al., 2000) . It has also been suggested that other proteins may have similar properties. These include fibroblast growth factor 1 and 2, and homeodomain (HD) containing proteins such as Hoxa-5, Hoxb-4, and Hoxc-8 (Prochiantz, 2000) .
The reason why PTDs are widely used are: (i) they confer the ability to deliver macromolecules into target cells, (ii) they are mainly independent of cell types, (iii) they are often very efficient, (iv) they are mostly stable, (v) they have very low or no cytotoxicity, (vi) they allow precise time and dose management and (vii) they usually cause no genetic modification of target cells. These features have made PTDs a promising alternative to deliver therapeutic proteins in a safe manner.
The potential of TAT PTD to deliver therapeutic proteins for treatment of cancer has been widely studied. Although many studies have proven the uptake of TAT PTD fusion proteins by target cells, the trans-activation potential of endogenous cellular genes by the 11 amino acids remains unclear. In addition, the full-length expression of TAT protein stimulates the growth of Kaposi's sarcoma-derived cells (Ensoli et al., 1990) and TAT transgenic mice develop Kaposi's sarcoma (Prakash et al., 2000) . However, the use of the 11 amino acids of TAT PTD is shown to be non-toxic in vivo experiments as this small PTD sequence is responsible for protein translocation only (Beerens et al., 2003) . To date, no toxic effects or tumour transformed cells of abbreviated PTDs have been reported elsewhere.
Intracellular Delivery of PTD-Conjugated Macromolecules
Most studies have shown the ability of PTD fusion proteins to deliver a cargo of biologically active proteins (Barka and Van der Noen, 1996; Ho et al., 2001; Noguchi et al., 2004) .
However, the ability of PTDs to deliver a cargo into cells is not limited only to proteins or peptides. Other macromolecules including non-organic molecules fused or linked to different PTDs have also been shown to transduce into target cells efficiently. These macromolecules are antisense, short-interfering ribonucleic acids (siRNA), peptide nucleic acids (PNA), iron nanoparticles, liposomes, and plasmids (Prochiantz, 2000; Vives, 2003; Wadia and Dowdy, 2003; Noguchi and Matsumoto, 2006b) (Table 2 ).
Possible Mechanisms of Protein Transduction
The mechanism of the internalization of PTDs is poorly understood. A few studies have shown that the internalization of TAT peptide is energy-dependent, requiring a temperature above 4 ºC and ATP (Brooks et al., 2005) . Nevertheless, many studies have demonstrated that the internalization of TAT-PTD, Antennapedia (Antp)-PTD or poly-Arginine (polyR)-PTD is not significantly inhibited by incubation at 4ºC, by inhibitors of endocytosis or by depletion of cellular ATP (Futaki et al., 2001) . Also demonstrated is that PTD internalization does not depend on a specific primary sequence; hence, it is receptor-independent (Vives et al., 1997) .
A few models have emerged to explain PTD uptake into target cells by the perpendicular insertion of amphipathic peptides, electrostatic interaction or endocytosis.
The first model is the perpendicular insertion of amphiphatic peptides into the membrane (Noguchi and Matsumoto, 2006b ). This mechanism involves assembled hydrophilic-hydrophobic lipids forming a channel through oligomerization, allowing efficient passage of hydrophilic cargo. However, several peptides can form pores at the cell surface, thus would be a threat to cell survival by inducing apoptosis. Antp-PTD may be categorized in this model due to the presence of penetratin, which is derived from the third helix of the Antphomeodomain protein (position 43-58 amino acids) (Prochiantz, 2000) . This peptide contains tryptophan (a hydrophobic amino acid) which is reported to be critical for the carrier ability in this model (Prochiantz, 2000) .
A second model proposes electrostatic interaction between peptides binding to the polar heads of lipids in the membrane, resulting in the formation of inverted micelles that engulf the cargo. Interestingly, this process occurs even at 4ºC, thus confirming that the mechanism is temperature-independent. The micelle that was formed earlier will then re-open either in the cytoplasm or nuclei of target cells. Some studies suggest that Antp-PTD might use this pathway (Berlose et al., 1996) . It has also been suggested that HIV-TAT, which shares similar charge characteristics may also use this mechanism (Ford et al., 2001) . However, a drawback of this model is that the inverted micelle formation would limit cargo size and it also requires the presence of hydrophobic amino acids, such features are absent in TAT PTD and polyarginine-PTDs.
A third model proposes cargo uptake by macropinocytosis, a type of endocytosis. It involves three phases which are: an electrostatic interaction with plasma membrane, macropinocytosis and retrograde transport (Figure 1 ). Most PTD-containing compounds are highly positively charged, while the plasma membrane is always negatively charged, thereby promoting PTD binding to plasma membrane due to electrostatic interaction. The initial step of transduction by PTDs occurs with electrostatic interaction with the plasma membrane, followed by the penetration into cells by macropinocytosis and release of the protein into cytoplasm and nuclei by retrograde transport to the Golgi apparatus and endoplasmic reticulum (Lord and Roberts, 1998; Noguchi and Matsumoto, 2006a) . Macropinocytosis is the invagination of the membrane forming a pocket which then forms a vesicle filled with extracellular matrix (including molecules within it). The endocytosis pathway appears to be critically important for the internalization of PTD-containing compounds.
HIV TAT Protein Transduction Domain
The HIV-1 trans-activator gene product, TAT, has been shown to be a regulator of transcription in latent HIV and essential for HIV replication (Karn, 2011) . It is an 86 amino acid protein consisting of two exons of 72 and 14 amino acids respectively. It has been reported that HIV-TAT added exogenously in culture media was taken up efficiently by target cells (Green and Loewenstein, 1988) . TAT amino acids 38-58 (the basic region of TAT) retain the transducing ability of HIV-TAT, which enables both nuclear and cytoplasmic uptake of the proteins (Mann and Frankel, 1991) . This study also showed that the uptake was not inhibited by trypsinazation, heparinazation and neuramidazation of the cells. Furthermore, they speculated that TAT binding to the cellular membrane was mediated through charge-interaction between the basic region of TAT and charged polysaccharides on the cellular membrane of the target cells (Mann and Frankel, 1991) .
In subsequent studies, Green and Loewenstein (1998) have shown that the improved TAT (YGRKKRRQRRR) fusion proteins transduced better into target cells. This improved synthetic TAT domain corresponds to a short 11 amino acid region which is highly positively charged at physiological pH with nine out of 11 of its amino acids being either Arginine or lysine. Since then, a series of synthetic TAT PTDs have been produced by optimising the deletion, addition and replacement of Arginine residues of primary TAT sequences, in order to determine their structure, activity relationship and the effect on internalization efficiency (Wender et al., 2000; Ho et al., 2001) .
A few studies have demonstrated the ability of synthetic HIV-TAT to deliver several peptides and proteins into target cells. This includes poly-Arginine (polyR) and poly-lysine, which exhibit even greater delivery efficiency compared to the primary sequence of the original TAT (Futaki et al., 2001; Noguchi et al., 2004) . Ho et al., (2001) reported the establishment of the improved synthetic TAT domains by α-helix modification of the original TAT structure (Figure 2) (Ho et al., 2001) . These synthetic TAT domains were named as PTD-3, PTD-4, PTD-5, PTD-6, PTD-7 and PTD-8. The transduction efficiency was increased 5-fold in both PTD-3 and PTD-6, 8-fold in PTD-5 and 33-fold in PTD-4. However, the transduction efficiency of PTD-7 and PTD-8 peptides containing nine or seven Arginine residues was comparable with the original TAT peptide. In this review, the most studied peptide, PTD-4 will be further 
PTD-4 (also known as TAT33)
PTD-4 was derived from the original TAT peptide by strengthening the putative α-helix with Ala (Alanine) residues (Ho et al., 2001) . The Arg (Arginine) content of TAT33 was limited to three, which were closely aligned down the face of the α-helix structure ( Figure 2C ). This was done by synthesizing the original TAT peptide with an NH2-terminal FITC-Gly (Glycine) residue followed by a Gly-Gly-Gly motif (Glycine). The Ala residues were then placed accordingly at the appointed positions (2, 4, 5, 6, 9 and 11). This synthetic TAT33 showed dramatically increased transduction efficiency (up to 33-fold) as compared to the original TAT peptide. The differences in the amino acid sequence between TAT-33 and TAT are shown in Figure 3 .
A study by Mi et al., (2000) demonstrated that the biotinlyted TAT33 and TAT peptides fused to avidin-beta-galactosidase were efficiently transduced in a variety of cell lines and primary cells (Mi et al., 2000) . However, the transduction efficiency of TAT33 was comparable with TAT peptides. Another study also demonstrated that mice injected with either TAT33 or TAT peptides had about ~100% of their blood cells transduced 30 minutes post-intravenous injection. Additionally, FACS analysis showed 5-fold intracellular PTD-4-FITC accumulation compared to TAT peptide (Ho et al., 2001) .
TATkappa (TATκ)
TATκ was generated by introducing mutations to destroy the two furin cleavage sites that were present within the original TAT peptide (Figure 3 ). Furin is a human gene also known as PACE (Paired basic Amino acid Cleaving Enzyme) which belongs to the subtilisin-like proproteinconvertase family. Furin is enriched in the Golgi apparatus but can translocate between the trans-Golgi network and the cell surface (Denault and Leduc, 1996) . The presence of these Furin sites in the TAT peptide results in the TAT peptide being cleaved from fusion proteins that are secreted via the constitutive pathway (Flinterman et al., 2009) . Thus, the secreted protein will not be able to enter target cells and is trapped in the culture supernatant.
Therefore, amino acid sequences RQRR and RKKR of TAT were modified by replacing five Ala residues within the peptide.
Flinterman et al., (2009) have established a novel system for the secretion of TAT fusion proteins using a mammalian expression system. Moreover, the ability of the secreted TATκ-GFP to efficiently transduce target cells was far greater than could be achieved with TAT-GFP or GFP alone. They also showed that the improved TATκ-GFP was efficiently secreted in culture supernatant compared to TAT-GFP confirming the presence of furin sites within the original TAT PTD. The secreted TATκ-GFP fused to Apoptin was also able to transduce into human osteosarcoma cell line (Saos-2) and induce apoptosis (Flinterman et al., 2009 ).
PTD usage in directing iPSC reprogramming
Using protein transduction approach, Zhou et al., (2009) (Zhou et al., 2009) . The mouse iPS cells were able to be expanded more than 30 passages, generate three primary germ layers and give rise to chimeric mice. Subsequently, Kim et al., (2009) reported successful iPSC generation in human newborn fibroblast (HNF) cells using multiple treatments of cell extracts from stable HEK293 cell lines expressing four reprogramming factors Oct-4, Klf4, Sox2, c-Myc (OKSM) fused to 9 Arginine (9R). Encouragingly, these human iPSC were also able to differentiate into functional dopamine (DA) neurons and could significantly rescue motor deficits in Parkinson Disease (PD) rat model (Rhee et al., 2011) . In a 2012 paper, Zhang et al., (2012) described the comparison between the usage of 11R and TAT as protein transduction method in generating iPSC. It was found that recombinant proteins fused with TAT (TAT-RF) has a higher transcriptional activity compared to 11R-recombinant protein (11R-RF) suggesting TAT as the better choice as PTD for protein-based delivery (Zhang et al., 2012) . The authors also reported higher efficiencies (0.012%) of iPSC reprogramming using five factors TAT-RF (with the addition of Nanog) combined with VPA treatment as compared to the previous studies (Zhou et al., 2009; Kim et al., 2009) . In a later study, Nemes et al., (2014) employed a strategy using transduction of GST-tagged TAT recombinant protein with a nuclear localization signal polypeptide (NLS) to further facilitate nuclear localization and successfully produced iPS cell lines which were able to incorporate into the blastocyst and generate chimeric offspring in mice (Nemes et al., 2014) . In terms of functionality of the recombinant reprogramming proteins, Thier et al., has established a lipid-rich albumin supplement in a low serum culture conditions for protein delivery of TAT-Oct-4, and TAT-Sox2. Both recombinant proteins are biologically active and able to be a substitute for their viral counterpart and in inducing iPSC reprogramming (Thier et al., 2010; Thier et al., 2012) .
Limitations and possible ways to overcome
Although several studies have reported successful generation of iPSC (Zhou et al., 2009; Kim et al., 2009; Zhang et al., 2012; Nemes et al., 2014 ) the efficiency of iPSC generation, using protein transduction approach is significantly lower (about 0.001% of input cells) compared to viral transduction approach (about 0.01% of input cells) (Takahashi et al., 2007; Park et al., 2008; Kim et al., 2009) . In an effort to improvised reprogramming protocols using PTD, Lee et al., 2012 observed significant differences in the genes expression profiles of cell reprogrammed with retrovirus and protein transduction method. It was reported that a toll-like receptor 3 (TLR3) pathway which enables efficient pluripotency reprogramming was activated only in retroviral induced cells as opposed to protein-based delivery . The study concluded that innate immunogenicity induced by viral particles could activate the expression of inflammatory genes and enhance epigenetics regulation in favor of reprogramming. However, application of TLR agonists called polyinosinic-polycytidylic acid (Poly I: C) together with recombinant proteins delivery could induce reprogramming efficiency in a shorter time . This strategy of using identified small molecules in enhancing the reprogramming efficiencies by recombinant proteins delivery method have also been employed in other studies with encouraging results (Zhou et al., 2009; Zhang et al., 2012) . Furthermore, the use of other small molecules such as butyrate, 8-bromoadenosine and thiazovivin in enhancing reprogramming efficiencies in other integrative and nonintegrative protocols have also been extensively reported (Mali et al., 2010; Lin et al., 2009; Wang and Adjaye, 2011) . Thus, further study is needed to explore the potentials of other small chemicals in supporting protein-based reprogramming as a way to overcome its limited reprogramming capabilities.
Another concern in direct delivery of recombinant factors into cells is the production and quality of recombinant proteins. TAT recombinant proteins could be produced using bacterial expression vectors in a highly efficient manner (Nagahara et al., 1998) however subsequent purification steps may caused recombinant proteins to be insoluble, denatured and could affect its biological activity (Singh et al., 2015) . Although numerous studies have shown that TAT and 9R denatured proteins could be refolded and regained its biological activity inside the mammalian cells (Kwon et al., 2000; Jin et al, 2001) , denatured proteins were also thought to be one of the main cause of unsuccessful reprogramming in human somatic cells (Pan et al., 2010) . As the quality of recombinant protein produced in mammalian cells is superior than the one produced in bacteria or yeast and largely employed in most pharmaceutical proteins (Wurm et al., 2004) , mammalian cells expression system could be a potential alternative in the production of correctly folded protein with a functional post translational modification in reprogramming applications (Hartley, 2012) .
To date there has been only one study employing mammalian cells HEK293 for expressing the OSKM 9R-recombinant proteins and its subsequent direct application of cells extract to target cells (Kim et al., 2009) . The authors observed that a single 16 hour exposure of protein treatment were not sufficient and concluded that continuous exposure to reprogramming factors is needed. They were only able to induce reprogramming in HNF through a multiple round of 16 hour protein treatments followed by 6 days incubation in hESC culture medium (Kim et al., 2009 ). This method while feasible could be laborious as multiple rounds of transduction is needed in a span of 8 weeks. As an alternative, we recently described a strategy to develop producer cell lines that could continuously express reprogramming factors for applications in the targeted cell lines through direct or indirect co-culture. Using a modified TAT protein TATκ, we have shown in our recent study a strategy in generating 293T cells secreting the pluripotent factors Oct-3/4 (Nordin et al., 2014) . The luciferase assay analysis showed a weak biological activity of Oct-3/4 protein, which confirmed that these producer cells secreted TATκ fused to Oct-3/4 protein in culture medium and could be uptake by haematopoietic cell lines, Jurkat and FDCP-1 cells. Although there are limitations that needed to be addressed, this strategy using cell lines in expressing recombinant proteins could be potentially applied in the future for the generation of iPS cells by protein transduction.
As an alternative to the perceived cumbersome approach in reprogramming using recombinant proteins, few studies have identified the feasibility of using self-penetrating proteins as an alternative approach. Native reprogramming Oct-4 protein were reported to be having self-penetrating capability and are able to be uptake into living cells as well as translocated to the nucleus (Harretheir et al., 2014) . Other studies also reported the ability of various versions of Nanog and Sox2 proteins in retaining and promoting their reprogramming capabilities (Theunissen et al., 2011; Aksoy et al., 2013) . Thus, with the use of reprogramming factor proteins either truncated or enhanced with transactivator domains, protein-based delivery method is still in the running towards the race in generating clinically safer iPSC.
Future directions
When taken together with previous reports, protein transduction method is a feasible alternative in replacing integration-based reprogramming methods. However, more basic questions such as immunogenicity, protein half-life, protein concentration, and modes of delivery are important questions that need to be answered before this type of therapy can be considered for long-term and effective human applications. At the molecular level, it is unclear how proteins behave when interacting with the cell membrane to mediate entry. It is thought that protein transduction across the cellular membrane resulted in partial or complete unfolding of the protein which may differ from one protein to another (Schwarze et al., 2000) . In order to obtain biologically functional protein, the transduced protein requires refolding once inside the target cells (Bonifaci et al., 1995) . Another consideration is to investigate phenotypic changes to determine how promising in vivo protein transduction really is by conducting animal studies.
Recently, a growing number of studies have shown the feasibility of protein transduction method in replacing viral delivery methods for directing specific lineage differentiation. Direct lineage reprogramming gained much attention recently as a more feasible way to produce specific functional cell lines for usage in regenerative medicine (Xu et al., 2015) . Specific lineage differentiation is mainly achieved through forced expression of known combinations of transcription factors specific to the cells such as cardiomyocyte (Ieda et al., 2010) , neural stem cells (Han et al., 2012) and insulin-producing cells (Xu et al., 2013) . Islas et al., (2012) first attempted to reprogram human dermal fibroblast into cardiac progenitor using recombinant TAT fused with MESP1 and ETS2 and obtained cardiac progenitor cells (Islas et al., 2012) .). Dai et al., (2014) used recombinant TAT proteins fused to OSK factors (Oct-4, Sox2, Klf4) combined with small molecules to reprogrammed adipose derived stem cells into corneal-endothelial (CE) like cells (Dai et al., 2014) . In a comparison study, myogenic transcription factors, MyoD tagged with TAT protein (TAT-MyoD) were shown to have higher reprogramming efficiency than its wild type MyoD protein which is also capable to facilitate transduction in mouse primary cells (Hidema et al., 2011) .
Aside from HIV-TAT usage in protein transduction, several other studies reported the use of other protein-based delivery in directing differentiation. Transduction of Pdx1 and NeuroD protein which have intrinsic PTD sequences with the combination of MafA fused with 11R were reported to induce differentiation of insulin-producing cells in mouse ES cells and mouse iPS cells (Kaitsuka et al., 2014) . Hu et al., (2014) reported the application of C-end Rule (CendR) peptide to deliver transcription factor Sox2 to retinal pigmented epithelial cell (RPE) for reprogramming of functional neurons (Hu et al., 2014) . Recently, one study applied QQ reagent which allowed efficient protein transduction (Li et al., 2008) modified with Gata4, Hand2, Mef2c and Tbx5 with the combination of growth factors could induce 80% of HDF into cardiac progenitor cells and improved cardiac function after myocardial infarction in rat model (Li et al., 2015) . Given these recent developments, protein transduction method has a great potential and future in directing lineage specific differentiation in vitro and in vivo, and subsequently could potentially be used in therapeutic application.
In general, a few improvements could be explored in the near future; (i) identifying new potential protein transduction domains (PTDs) and improving the potential of existing PTDs to increase transduction into target cells, (ii) identifying potential chemical molecules that are nontoxic to enhance transduction into target cells, (iii) to increase the refolding rates of transduced full-length proteins and domains, and (iv) to produce sufficient physiological levels of secreted proteins for large scale studies. As regards to the usage of HIV-TAT as PTD, more optimization needs to be performed in order to improve the protein transduction of pluripotency factors fused to TAT domain. As reported in our study, TATκ fusion with pluripotent factors could be potential method for directing reprogramming of cells (Nordin et al., 2014) . However there is a need to identify the problems related to secretion of TATκ fusion proteins, to study the biological function of TATκ fusion proteins in target cells and, to establish in vitro functional assays for assessment of these fusion proteins.
Therefore, understanding and improving the mechanisms involved in the direct delivery of PTD fusion proteins into target cells for iPS reprogramming could give the answer to these questions and allow an accurate assessment of the potential that this approach could offer for human therapeutic applications.
In conclusion, the protein transduction system has several advantages over integrating vectors; (i) they effectively eliminate the potential risks associated with chromosomal integrations, and (ii) they are a simpler and faster approach without the need for sequential selection of integration-free transduced cells, and (iii) the continuous expression of pluripotency factors by producer cell line which can be withdrawn at any time point in culture as compared to permanent gene expression in integrating viral vector. In addition, the assumption that a protein transduction approach, as opposed to genetic modification avoids the risk of malignant transformation requires extensive investigation to be verified by both in vitro and in vivo studies. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calvo, M., and Fischer, A. (2003) . A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348, 255-6. Figures   Figure 1: The macropinocytosis model of protein transduction. The primary mechanism of protein transduction is an electrostatic interaction between PTD-conjugated macromolecules and the plasma membrane, followed by the penetration into cells by macropinocytosis, and release to the cytoplasm and nuclei by retrograde transport (Noguchi and Matsumoto, 2006a) . Murine HSCs (Barka et al., 2000) TAT-HoxB4 
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